40d ago

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.

1 reportus_mainstream

Claim audit

No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.

All coverage

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

rss:cnbc-topus_mainstream40d ago kagi ↗

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.